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Traumatic brain injury (TBI) is a major medical crisis without any FDA-approved
pharmacological therapies that have been demonstrated to improve functional outcomes.
It has been argued that discovery of disease-relevant biomarkers might help to guide suc-
cessful clinical trials forTBI. Major advances in mass spectrometry (MS) have revolutionized
the field of proteomic biomarker discovery and facilitated the identification of several candi-
date markers that are being further evaluated for their efficacy asTBI biomarkers. However,
several hurdles have to be overcome even during the discovery phase which is only the
first step in the long process of biomarker development. The high-throughput nature of
MS-based proteomic experiments generates a massive amount of mass spectral data pre-
senting great challenges in downstream interpretation. Currently, different bioinformatics
platforms are available for functional analysis and data mining of MS-generated proteomic
data. These tools provide a way to convert data sets to biologically interpretable results
and functional outcomes. A strategy that has promise in advancing biomarker develop-
ment involves the triad of proteomics, bioinformatics, and systems biology. In this review,
a brief overview of how bioinformatics and systems biology tools analyze, transform, and
interpret complex MS datasets into biologically relevant results is discussed. In addition,
challenges and limitations of proteomics, bioinformatics, and systems biology in TBI bio-
marker discovery are presented. A brief survey of researches that utilized these three
overlapping disciplines in TBI biomarker discovery is also presented. Finally, examples of
TBI biomarkers and their applications are discussed.
Keywords: proteomics, biomarkers, traumatic brain injury, bioinformatics, systems biology
INTRODUCTION
Tremendous efforts have been put into the discovery of biomark-
ers that can diagnose disease or injury. A quick search for scholarly
articles that include the word biomarker can yield more than half
a million hits. However, the overall status of biomarker develop-
ment and clinical validation is very disappointing. There are only
a handful of novel biomarkers that are of clinical relevance, and
the rate at which a biomarker is introduced to the market is dis-
mal. One estimate shows that since 1998, new protein biomarkers
that were approved by the US Food and Drug Administration fell
to one per year (Rifai et al., 2006). The reasons for this trend
are numerous and one strategy to reverse the fall is a better under-
standing of the whole process itself. One key strategy in hunting for
that robust biomarker is the combination of scientific disciplines.
In traumatic brain injury (TBI), an interdisciplinary approach is
employed by combining the methods and tools from three fields,
namely, proteomics, bioinformatics, and systems biology.
Proteomics is the study of protein populations or proteomes.
The term “proteome” was coined in 1995 (Wasinger et al., 1995)
to describe the protein complement of a genome. This came after
realizing that at least half of the proteins encoded by the human
genome have no known functions. The move to study the message
(mRNA or cDNA) and focus on the product of the message (pro-
teins) gave birth to proteomics. Proteomics assesses the expression
level of proteins, post translational modifications and interac-
tions of proteins within a tissue, cell, subcellular compartment,
or biofluid. The goal is to obtain a large scale and a global view of
physiological conditions and disease processes. However, study-
ing the global systems of proteins has produced a large amount
of data, and making sense of the complex data generated became
a problem. In the beginning, it was clear that processing a vast
amount of data requires the aid of computers. Like genomics a
decade ago, proteomics tackled the problem by enlisting the help
of bioinformatics and later on, systems biology.
Bioinformatics combines mathematics and computer tech-
nology to deal with the analyses of large numbers of proteins
while systems biology unveils the global network of physiolog-
ical environments. Bioinformatics has become an integral part
of proteomics, strategically mining data for sensible results. Sys-
tems biology on the other hand tries to look at the big picture
by mapping interactions of isolated proteins, akin to looking at
the ecosystem of the whole forest, rather than just the individual
trees.
The triad of proteomics, bioinformatics, and systems biology
has been applied to study protein behaviors in myriad disease
pathologies. It was no different with neurological conditions such
as TBI,Alzheimer’s disease, and stroke. Neuroproteomics (Choud-
hary and Grant, 2004), a field under the proteomics umbrella, has
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zeroed in these disorders, extracting insights into the dynamics
and interactions of proteins in these disease states (Ottens et al.,
2006, 2010; Bayes and Grant, 2009; Alzate, 2010; Shoemaker et al.,
2012).
One of the neurological conditions that received a fair amount
of media attention lately is TBI. Although TBI is known as the
“silent epidemic,” the public is beginning to be aware of the injury
as war veterans come home from war-zone blasts. Even the mil-
itary has acknowledged that TBI is the “signature injury of the
conflicts in Iraq and Afghanistan” (Risdall and Menon, 2011).
Increasing media coverage to concussive injury has increased
lately. This is partly due to the increase in suicides of football
players. High profile cases of professional football players have
captivated the public, highlighted by the suicide of Dave Duerson.
Mr. Duerson, a professional football player, was suspected to have
suffered TBI during his playing years. He was found dead with
a gunshot to his chest, not in his head, to preserve his brain for
science.
Statistically, TBI is one of the leading causes of disability in
the United States. It is considered one of the major health prob-
lems annually claiming 5% of the lives of the two million victims.
Around 25% are hospitalized and approximately half are treated
and released after emergency care (Smith et al., 2003; Johnson et al.,
2004). It is estimated that by 2030, the public health impact of TBI
will increase (Mathers and Loncar, 2006). This should alarm us
as road traffic accidents will be the most common cause of blunt
trauma, making TBI the fourth leading cause of disability.
The disturbing reality for victims and their families is that cur-
rently, there are no FDA-approved treatments or therapy (except
for pain relievers) that can alleviate the effects of TBI. One of
the most pressing needs however, is the accurate diagnosis and
monitoring of patients. Physicians should be guided if patients
respond to the treatment and improve. But to this day, clin-
icians are limited only by parameters such as brain pH, pO2,
intracranial pressure (ICP), and temperature. Brain imaging tech-
niques such as Computer Tomography (CAT) and Magnetic
Resonance Imaging (MRI) scans have provided information of
damaged regions non-invasively, but only looking at the injury
in a short time. The limitations of traditional diagnosis have
hindered the overall progress in understanding the condition,
highlighting the need for more accurate diagnostic tools. The
goal is that a robust biomarker or panels of biomarkers will
complement existing diagnosis, and eventually replace the more
traditional ones.
In this paper, advances and limitations of proteomics, bioin-
formatics, and systems biology will be discussed. We shall then
try to integrate the three fields in relation to biomarker discovery,
and limiting the discussion only to protein biomarkers in TBI.
This article is structured as follows. In Section “Biomarkers, TBI
Models, Proteomics, Bioinformatics, and Systems Biology, Their
Definition,”we define biomarkers,TBI animal models,proteomics,
bioinformatics, and then systems biology. In Section “Protein Pro-
filing,” we shall review the methods, challenges, and technical
difficulties inherent in identifying proteins. Section “Biomarker
Applications” deals with the present panels of proteins that can be
used as a biomarker for TBI.
BIOMARKERS, TBI MODELS, PROTEOMICS,
BIOINFORMATICS, AND SYSTEMS BIOLOGY, THEIR
DEFINITION
Biomarkers are indicators of normal biological processes or dis-
ease states. A biomarker can also be a gage of pharmacological
response in therapeutic interventions (Lesko and Atkinson, 2001).
The idea in biomarker discovery is that organs secrete specific
molecules that can indicate a physiological malfunction. In gen-
eral, these are any biomolecules that can serve as a fingerprint
showing up from samples of affected tissue or peripheral fluids of
the affected area. In the context of TBI and proteomics, ideal bio-
markers are proteins that are only present in the brain, leaked out
from the blood brain barrier and into the person’s blood or cere-
brospinal fluid (CSF) during or after brain injury. These molecular
signatures should be proportional to the impact and the extent of
damage in the brain, and should reflect differences between age
groups and sex.
Numerous animal models of TBI have been developed to
understand the heterogeneous nature of brain injury (recently
reviewed by Chopp et al.) (Xiong et al., 2013). Due to their low
cost and the presence of more standardized outcome measure-
ments, rodent models are particularly used to study TBI although
bigger animals are closer to human physiology. Controlled cortical
impact (CCI) uses a controlled degree of impact by a pneumatic
or electromagnetic impact device (Lighthall, 1988; Dixon et al.,
1991). Penetrating ballistic-like brain injury (PBBI) model mimics
severe to moderate TBI such as gunshot wounds. PBBI is induced
by transmission of high energy projectiles and a leading shockwave
producing a temporary cavity in the brain that is many times the
size of the projectile itself (Williams et al., 2005). Another widely
used model is the fluid percussion injury (FPI) where a contu-
sion force is incurred by the movement of a fluid in a chamber.
In the drop-weight impact acceleration injury, the skull (with or
without craniotomy) is exposed to a weight that is dropped from
a certain height and injury severity can be altered by adjusting the
mass of the weight and the height from which it falls. The more
recent TBI models are the blast models that mimic TBI induced
by explosive devices. Blast-induced brain injuries have been pre-
dominant among military personnel who have been exposed to a
blast but do not have external injuries (Warden, 2006; Benzinger
et al., 2009). Different variations of blast TBI animal models have
been developed to elucidate the effects of primary blast waves on
the brain (Wang et al., 2005; Cheng et al., 2010; Svetlov et al.,
2010; Risling et al., 2011). Elucidation of the mechanisms of blast
injury, identification of biomarkers and, eventually, the develop-
ment of strategies for mitigating blast-induced brain injury will
benefit from further design optimization, characterization, and
standardization experimental parameters of blast TBI models.
While TBI can occur as a result of auto accidents, violence, or
sports injuries it has left the shadows with the war in Iraq and
Afghanistan. Twenty-first century warfare exposes military per-
sonnel to blast injuries resulting from high order explosives. The
Kevlar helmet, although an excellent protection against penetrat-
ing brain injury, offers little protection from blast injuries (Lew,
2005; Okie, 2005). Accurate statistics are not currently available,
but it is estimated that more than 50% of all casualties from the
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Afghanistan and Iraq theaters have sustained head injuries (War-
den, 2006) compared to 15–25% from twentieth century conflicts
(Carey, 1996). Of the 1.4 million TBIs that occur annually, the
vast majority, between 75 and 90% are mild or moderate (mTBI)
(Jager et al., 2000; Gerberding, 2003). Mild and moderate TBI,
also called concussion, occurs when an impact or forceful motion
of the head results in a brief alteration of mental status, such
as confusion, disorientation, brief memory loss, or brief loss of
consciousness. Because they produce a number of imprecise per-
ceptual symptoms without diagnosable objective structural brain
alterations, mTBIs are challenging to diagnose (Lyeth et al., 1990;
Hamm et al., 1993; Kibby and Long, 1996; Margulies, 2000). Fur-
thermore, many sufferers fail to recognize the potential severity
and seriousness of their injury thus do not seek medical attention
(Alexander, 1995; Kushner, 1998). TBI is thus under-diagnosed
and under-represented in medical statistics. However, even brief
alterations in mental status can inflict profound and persistent
impairment of physical, cognitive, and psychosocial functioning
(Binder, 1997; Ruff and Jurica, 1999). Furthermore, TBI is an epi-
genetic risk factor for Alzheimer’s and Parkinson’s diseases (Smith
et al., 2003; Szczygielski et al., 2005). Although TBI is a major
focus of casualty care in combat areas and the principal cause
of mortality and morbidity due to improvised explosive devices
(IEDs) and other hazards, there are no FDA-approved pharmaco-
logic therapies that have been demonstrated to improve functional
outcomes.
Proteomics is defined by many as the study of the protein com-
plement of the genome, the proteome (Blackstock and Weir, 1999;
Stults and Arnott, 2005). The proteome is the set proteins from
the whole organism or specific organ at specific physiological
conditions.
Several definitions of bioinformatics can be found in the lit-
erature today. What suits us is the idea that bioinformatics is a
tool to mine vast amounts of data using computer technology and
mathematics (Hagen, 2000; Kumar and Mann, 2009).
Systems biology came into picture as soon as proteins were
identified from proteomics experiments. For example, low concen-
tration proteins can now be identified in an injured brain; however,
a list of individual proteins may not make sense. To understand
the connections of isolated proteins, systems biology came in.
The science of systems biology is still considered to be in its
infancy and a consensus on its definition has not been fully reached
(Ideker et al., 2001; Kitano, 2002a,b; Chuang et al., 2010). For us,
it is an approach to study the complex interactions of biologi-
cal systems. It examines, assembles, and maps the properties and
regulations of tightly interconnected biological systems.
PROTEIN PROFILING
Identification of proteins is one of the main goals of biomarker
discovery. The conventional method of identifying proteins as a
marker for disease is by measuring a specific compound known to
be part of the pathophysiology. In TBI for example, the presence of
glial fibrillary acidic protein (GFAP) in the blood can mean dam-
age to the glia. Also, tau and spectrin protein breakdown products
in the blood indicate damage to the axons. One can also exam-
ine the unregulated breakdown products of necrotic cell death.
Breakdown products of calpain mediated proteolysis can be used
as biomarkers of TBI. This is the same for products of apoptotic
cell death, from the activation of caspase (Büki et al., 1999; Farkas
et al., 2005; Svetlov et al., 2009; Risdall and Menon, 2011).
A novel method, which is the subject of this review, is the data
driven and high-throughput approach of discovery. In this strat-
egy, the samples from normal and TBI patients are compared,
screening for differences between the two. This approach con-
sistently uses mass spectrometry (MS) and most of the time it
is discovery driven instead of being hypothesis driven (Stults and
Arnott, 2005). In discovery driven types of experiments, informa-
tion is collected and then patterns are sought. Unlike hypothesis
driven research that disproves or proves a defined hypothesis, dis-
covery driven research collects a huge amount of information first
then extracts questions and answers from lots of data. It may
sound like a “blind shot” to find answers, but our current technol-
ogy enables us to do this. If history is a good indicator, it worked
with genomics and metabolomics, so performing discovery driven
experiments with an entire proteome is logical.
HISTORICAL BACKGROUND
It was almost 40 years ago when two-dimensional electrophoresis
was invented and described in a paper (O’Farrell, 1975), giving
way to the separation of more complex mixtures. A few years
after, in the early 1980s, the first profiling of human CSF (Merril
et al., 1983) and mammalian brain (Klose and Feller, 1981) were
reported. These started the systematic classification of proteins
from the brain. By the mid-80s, the first proteomic database SWIS-
SPROT was established (Bairoch and Boeckmann, 1991; Bairoch
and Apweiler, 1997; Peitsch et al., 1997). In the end of that decade,
two ionization techniques for MS analysis were introduced, mak-
ing large protein analyses possible (Karas and Hillenkamp, 1988;
Fenn et al., 1989). High-throughput and gel free proteomics came
into being when liquid chromatography (LC) was integrated with
MS around 1996 (Appella et al., 1995).
Ten years later, the profile of a mouse’s brain was created, iden-
tifying 7,792 proteins (Wang et al., 2006), ranging in abundance
from tens of copies to hundreds of thousands of copies.
MS-BASED NEUROPROTEOMICS WORKFLOW
In a typical neuroproteomics experiment, proteins from the brain
or spinal cord tissue are extracted as a mixture of proteins.
Depending on the experiment, obtaining the proteins can be done
with tissue homogenization, cellular fractionation, or affinity frac-
tionation. Then the complex mixture is further separated to reduce
its complexity.
Three of the common separation tools for protein separations
are two-dimensional electrophoresis (2DE), one-dimensional
electrophoresis (1DE), and a two-dimensional LC. In the more
common bottom-up proteomics, after subjecting a sample to one
of the three methods mentioned above, the proteins are then
digested by an enzyme prior to analysis by MS. After protein
separation and digestion, the resulting peptide mixture is fur-
ther resolved by a nanoflow liquid chromatography (nanoLC)
based on the peptides hydrophobicity prior to introduction into
the mass spectrometer by nano-electrospray ionization. Many
TBI proteomic biomarker studies have relied on the bottom-up
approach. Putative protein biomarker candidates were identified
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in rat CCI model using 1D-SDS-PAGE prior to bottom-up pro-
teomic analysis (Will Haskins). An improved two-dimensional
platform employing a protein pre-fractionation step by cation-
anion exchange and ID-SDS-PAGE prior to bottom-up proteomic
analysis was used in subsequent TBI biomarker studies from our
group (Kobeissy et al., 2006; Ottens et al., 2007). Kochanek’s group
was the first to use 2D-PAGE in TBI biomarker study (Jenkins
et al., 2012). Siman et al. (2004) performed MALDI-MS follow-
ing 2D-PAGE of proteins released from TBI cell culture model to
identify acute TBI protein biomarkers. 2D-PAGE and mass spec-
trometric analysis have been implemented in oxidative stress TBI
biomarker studies (Opii et al., 2007). An alternative to the above
approach is shotgun proteomics (Wolters et al., 2001; McDon-
ald and Yates, 2002, 2003; Wu and MacCoss, 2002). The complex
mixture in shotgun analyses is directly digested without prior sep-
aration or fractionation. Variations of this method exist but all
shotgun proteomics begins with a mixture of proteins. For exam-
ple, a complete protein digest without prior separation can be
separated by LC and then analyzed by MS in real time. A shot-
gun proteomic approach based on nanoLC in conjunction with
matrix-assisted laser desorption/ionization time of flight tandem
MS (MALDI-TOF MS/MS) was utilized to quantitatively analyze
the protein content of consecutive ventricular CSF samples of
severe TBI patients (Hanrieder et al., 2009). Recently, our group
has applied shotgun proteomics to profile the neuronal-glial bio-
markers released into conditioned media collected from MTX-,
NMDA-, and STS-treated cell cultures (Guingab-Cagmat et al.,
2012).
One application of MS is in the identification of intact proteins
(i.e., without enzyme digestion) referred to as top-down approach.
In the context of proteomics, top-down is an emerging technology
but more difficult to implement compared to the more widely used
bottom-up approach. For proteomics, top-down has the advantage
of preserving the forms of proteins present in vivo by measuring
them intact, rather than measuring peptides produced from them
by proteolysis. This approach is particularly useful in characteriza-
tion of post translational modifications which may be challenging
to analyze with enzymatic digestion. But in order to perform this
kind of analysis, an expensive instrumentation is a requirement.
Most of the laboratories however don’t have the luxury of having
a Fourier Transform Ion Cyclotron Resonance Mass Spectrome-
ter (FT-ICR-MS) (Marshall et al., 1998; Shi et al., 1998), or the
relatively less expensive Orbitrap mass spectrometer (Thermo’s
Orbitrap Elite) or access to these kinds of instruments. The very
advantage of these kinds of instruments is that they are highly
sensitive and capable of ultra-high resolution. The downside how-
ever is that maintenance of FT-ICR-MS is very expensive since it
requires cooling a very strong magnet, on top of an expensive
machine. The Orbitrap mass analyzer traps ions using an electro-
static field, instead of a magnet. The cost and maintenance are
now relatively lower, but still an expensive machine. Possibly due
to these reasons, top-down proteomics is yet to be accepted and
widely implemented to TBI studies.
Presently, technologies that focus on identifying less abundant
proteins are gaining traction. These methods are usually based on
MS, and the requirement is that a step prior to injection into the
mass spectrometer is added. Broadly, the steps prior to MS can be
categorized into chemical modifications and direct enrichments.
An example of chemical modification is affinity tagging. A popular
tagging method is ICAT or isotope coded affinity tags. It is used
to quantify and identify plasma biomarkers of TBI. These kinds
of experiments can identify several candidate proteins, from tens
to hundreds. Protein biomarkers in serum of pediatric patients
with severe TBI were identified by ICAT-LC-MS/MS (Haqqani
et al., 2007a,b). Another approach is isobaric tagging for relative
and absolute quantification (ITRAQ). An example is the study by
Crawford et al. (2012) on the identification of protein markers
of TBI outcome. Here, CCI mouse model was used to identify
plasma biomarkers specific to mild or severe TBI at 24 h, 1 month,
or 3 months post-injury. In addition, they used apolipoprotein E 3
and 4 transgenic mice, which demonstrate relatively favorable and
unfavorable outcomes respectively, following TBI to identify pro-
teins that are significantly modulated in response to the TBI*APOE
genotype interaction representing potential prognostic biomark-
ers. ITRAQ has also been applied in the identification of serum
biomarkers and demonstrating their potential for predicting ele-
vated intercranial pressure in TBI patients (Hergenroeder et al.,
2008).
Direct enrichment entails some separation prior to MS analy-
sis. These separation strategies usually apply chromatography,
SDS-PAGE, or antibody. For example, cation-exchange chro-
matography, SDS-PAGE, and then LC, were performed on a
rat CCI model to identify putative protein biomarkers post
48 h TBI (Kobeissy et al., 2006; Ottens et al., 2007). The
results included 59 differential protein components of which 21
decreased and 38 increased in abundance after TBI. Proteins
with decreased abundance included collapsing response medi-
ator protein 2 (CRMP-2), glyceraldehyde-3-phosphate dehydro-
genase, microtubule-associated proteins MAP2A/2B, and hexok-
inase. Conversely C-reactive protein, transferrin, and breakdown
products of CRMP-2, synaptotagmin, and alphaII-spectrin were
found to be elevated after TBI.
BIOINFORMATICS IN IDENTIFYING PROTEINS
Proteomics experiments to identify proteins are tedious. It is akin
to breaking a huge and complicated puzzle and then putting the
pieces together again. With our puzzle analogy, manual integration
of the pieces (smaller peptides) is impossible to complete without
the help of computers.
The need for algorithms to identify proteins married bioinfor-
matics to proteomics. Once the developers of algorithms were on
board, they needed to know some of the rules of protein science.
One of these is for example in sample digestion. If trypsin was used
in the digestion, this enzyme is known to only cleave proteins after
both lysine and arginine, as long as the next amino acid sequence
is not proline (Fraser and Powell, 1950). This and many other rules
have to be grasped by software developers.
Other rules that computer scientists should fundamentally
understand are mass spectra. Historically speaking, MS of digested
proteins was performed predominantly by matrix-assisted laser
desorption ionization time of flight or MALDI-TOF. MALDI
(Karas and Hillenkamp, 1988) is a kind of ionization that is
regarded as “soft,” enabling large biomolecules to be ionized and
carried to the mass analyzer. The ionization requires two things:
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the energy from the laser and the matrix. Although the mechanism
of MALDI is still in question, it is believed that the ionization of the
analyte happens after the matrix absorbs the energy from the laser,
the matrix imparting the energy to the analyte, thereby ionizing
the sample.
Once the calculated experimental spectrum or mass lists are
produced, these are matched against a protein database. Another
set of spectrum, a theoretical one, is also matched to the database.
Theoretical and experimental results are compared and com-
puted, to have confidence in the identified proteins (Maggio and
Ramnarayan, 2001; Colinge and Bennett, 2007; Matthiesen, 2007;
Webb-Robertson and Cannon, 2007).
The above method, performed in MALDI-TOF, is commonly
referred to as peptide mass fingerprinting (PMF). PMF’s require-
ment is that a single spectrum should contain the peptides of the
protein. The introduction of LC and ESI however removed the sin-
gle spectrum requirement. With LC experiments, identification of
peptides became more challenging.
In a typical LC-MS/MS analysis, one can predefine the num-
ber of the most intense peaks to be selected for dissociation. For
example, in our laboratory, we subject the 10 most intense peptide
signals to tandem MS (MS/MS) fragmentation (data dependent
scanning). Every second, the MS analyzes the sample and pro-
duces a full MS Scan of ∼20,000 intact peptides. Based on the
initial full MS scan, the mass spectrometer, following the user’s
settings, selects again and fragments up to 10 distinct peptides,
producing another set of MS/MS spectra.
During the selection of peptide however, the same peptide can
be selected more than once. To avoid this problem, a dynamic
exclusion strategy is usually implemented. For example, if a pep-
tide was selected three times already over the span of 18 s, that
peptide is placed in the exclusion list for the next 25 s. The cycle
of subjecting the 10 most intense peptides to MS/MS and the pro-
duction of s full MS scan is repeated until the chromatography
is done.
Tandem MS (MS/MS) provides an additional degree of infor-
mation in identifying proteins. One can see that in a single analysis,
a large number of MS/MS spectra are produced. Assigning the pep-
tide sequences responsible for the generation of the observed frag-
ments is challenging. Since the fragmentation process in MS/MS
follows some rules, rules that software developers exploit, it is now
possible to identify proteins that are subjected to tandem MS.
Collision of an inert gas with large proteins (such as collision
induced dissociation or CID) fragments the proteins apart into
smaller peptides. This happens inside the trapping cell of the MS.
The breaking of proteins follows a certain type of fragmentation
pattern (most researchers follow the nomenclature introduced by
Roepstorff and Fohlman, 1984). It is widely known that proteins
in the gas phase can break into set of ions (“b, y, and a” type ions)
(Bencsath and Field, 1988; Polfer et al., 2005; Liu and Schey, 2008;
Chen et al., 2009; Paizs and Mann, 2012).
Even though the rules of producing specific ions are clear, prob-
lems still exist. Some compounding factors happen when there can
be some additional peaks resulting from neutral losses (b-H2O,
y-H2O), ammonia loss (b-NH3), from contaminating peptides,
small molecules, or even missing peaks. Some peaks can be shifted
due to amino acid modifications. And as in any other analytical
signal, the presence of noise even complicates the spectrum inter-
pretation. These hinder the peptide sequence assignment to each
spectrum.
SOFTWARE FOR PEPTIDE AND PROTEIN IDENTIFICATION
The process of protein identification benefited from the matu-
ration of two technologies, the computer hardware and database
software. Protein database search has become a powerful approach
to address the challenge of protein ID. Currently, numerous bioin-
formatics software for computational peptide identification from
MS/MS data are available in the market (Xu and Ma, 2006).
The first computer program to use a database search was
Sequest. Acquired by Thermo Scientific and commercially avail-
able through Proteome Discoverer (Thermo, San Jose, CA, USA.
www.thermo.com), the development of this software can be traced
back to Yates et al. (1995) in the early 1990s at the University of
Washington. The scoring function in this package is heuristic in
nature, and it was considered to be the first really useful bioinfor-
matics technique in the field of proteomics. The software integrates
correlational analysis between data dependent mass spectral scans
and a FASTA protein database. Sequest searches and identifies
peptides and the corresponding modifications that the user specif-
ically queries. Using these peptide identifications, one can make
inferences about the proteins in the sample.
In Sequest, the first process is the extraction of tandem mass
spectra from the raw file. Theoretical candidate sequences from
the digested proteins in the database are listed. Within a defined
tolerance set by the end user, the algorithm determines which one
matches the experimental peptides’ molecular weight. A compar-
ison of the candidate’s b and y ions to the experimental spectra
are made and scored as primary score (Sp). The primary score
sorts the candidate sequences in descending order. Sequest uses
two scoring functions, so after the initial candidate sequence is
determined; the top peptides are taken off the list. A second func-
tion rescores the hits by computing a cross correlation, taking into
account their height and mass position. The new candidates are
resorted in descending order. After taking into account the possible
random matches, the final list after resorting is the final SEQUEST
scores (Xcorr). These top hits are reported back and stored into
the search files (.msf). In addition to Sequest’s Xcorr, users can
export several other parameters such as Sp or DeltaCn. DeltaCn
measures how good the XCorr is relative to the next best match.
Overall, Xcorr is a robust measure of how accurate the match was
between theoretical and experimental peaks.
Several algorithms came after Sequest. MASCOT (Perkins et al.,
1999) and X! Tandem also became popular search engines. Owned
by Matrix science, MASCOT is commercially available, although
the scoring has never been patented or published. With MASCOT,
the accuracy score is probability based. This is measured by Ion
score, and a P-value gives a relative score. On the other hand, X!
Tandem is an open source tool. These search engines approach
the problems differently and uses different algorithms. With X!
Tandem, hyper score and E-value are two of the parameters
calculated.
In some instances however, there are situations that a protein
database is not yet available. This can happen in the analysis of an
organism where its genome sequence is incomplete or unavailable.
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In addition, if one is only interested in identifying novel isoforms of
the protein, often, the database is unavailable. A popular approach
to tackle the problem is to perform a de novo (Shevchenko et al.,
2001) sequencing. Spectrum identification in de novo analysis uses
a database of candidate peptides consisting of all possible lin-
ear amino acid sequences (Xu and Ma, 2006). This method can
be used also for searching peptide homologs and modifications.
In the early days of the development of algorithms in de novo
sequencing, researchers in this field attempted to reconstruct pep-
tide sequences by making all of the amino acid combinations. This
was not applicable though due to generic problems. However, the
market has seen software for de novo sequencing. Algorithms in de
novo sequencing usually filter the experimental mass list to remove
noisy peaks. PEAKS (Ma et al., 2003) and PepNovo (Frank and
Pevzner, 2005) are some of the software that facilitate fast de novo
peptide identification. A hybrid between the de novo sequencing
and protein database searching is known as tag-based approach.
Sequence-tagging uses the de novo analysis to identify subpep-
tides or sequence tags hypothesized to occur in the sequence. In
these kind of experiments, information is usually extracted from
database that contains the tags (Mann and Wilm, 1994).
Since the sequencing results of de novo shows a close resem-
blance compared to the output of known protein database,de novo
is usually used in validating the accuracy of database-derived pro-
tein identifications (Shadforth et al., 2005). Validation of the accu-
racy of one’s result is one of the issues that are tackled by end users
and software developers. Reviewers of top proteomic journals have
pushed to address this issue. This will be discussed next.
FALSE DETECTION RATE
False detection rate (FDR) measures the false positive proteins
identified. FDR provides a statistically meaningful estimate of the
uncertainty in protein identification. It is usually a good validation,
for example in large data sets of brain proteins. Most proteomic
journals require FDR to be reported. In measuring FDR, a decoy
database is usually used. Decoy database for FDR calculations were
pioneered by Gygi and co-workers, in which decoys consist of
a randomized or scrambled sequence database (Elias and Gygi,
2010). The parameters used in regular search are applied to the
decoy database search. Matches using decoy database search is not
expected to be significant, and the number of matches found in
a decoy search is a good estimate of the real FDR in the regular
forward sequence database search.
Although there are two ways to implement a search in a decoy
database, users preferentially use one from the other. The most
preferred method is the concatenated approach. In this method,
the decoy and the non-decoy databases are linked together.
The other method is a more conservative approach. The search
of MS/MS data is separate from non-decoy to decoy databases and
the number of matches for each database is counted.
SYSTEMS BIOLOGY
After a database search and identification of proteins, usually
a huge library of information is generated. The next step is to
know the protein’s functions and the connections of these iden-
tified proteins. Rather than focusing on individual molecular
components, systems biology seeks to understand the dynamics
that govern protein networks, the functional set of proteins that
regulate cellular decisions related to TBI. From the perspectives
of drug discovery and diagnostics, systems biology gives impor-
tant and practical clues concerning the pathways relevant to brain
injury and the effects that drugs might have on them. Therefore,
it enhances the entire biomarker and therapeutic drug discov-
ery, development, and commercialization process (cite Systems
bio approach/Theranostics). Recently, protein biomarkers of TBI,
induced by penetrating ballistic-like injury model (PBBI), were
identified by the proteomics followed by systems biology analy-
sis (Boutté et al., 2012). These proteins are ubiquitin carboxyl-
terminal isozyme 1, tyrosine hydroxylase, and syntaxin-6. Using
semi-quantitative western blotting analysis, the said proteins were
found to be elevated after 72-h post-injury compared to con-
trol. It should not be a surprise that Ubiquitin carboxy-terminal
hydrolase L1 protein (UCHL1) is already in clinical trial as a
biomarker.
The connections or network of connections are pictured using
nodes and links. The nodes can be a biomolecule, such as proteins
or DNA. The link or the connections between these nodes repre-
sent the biochemical interactions or the connections can highlight
relationships between nodes, such as the strength of predicted
binding or physical interactions. Theories in the science of systems
study and statistical mechanics, in conjunction with graph the-
ory, can be applied to glean insights about the network. Mapping
the connection of these proteins is the driving force of pathway-
based biomarker discovery and diagnosis. Particularly in TBI,
upregulated proteins after the injury are hunted and identified as
possible diagnostic biomarkers. Numerous scientific publications
containing networks of cellular pathways are scattered through-
out archives and available data are growing fast. Historically, most
of the repositories of large scale sequencing projects were mostly
nucleic acid and amino acids. But this gave way to other biomol-
ecules such as proteins. Lately, databases that store proteins have
been steadily increasing. For example, the Database of Interacting
Proteins can be queried for known protein-protein interactions or
PPI (Xenarios et al., 2001).
The nuts and bolts of these bioinformatics software, which
systems biology has integrated, are geared toward people with a
strong background in computer science and statistics. Since we
are the end users of this technology, we will focus on software that
we are familiar with and have been using. Readers are directed
to other sources of in-depth reviews with regards to systems
biology. Three commercially available pathway analysis software
include Pathway Studio (Ariadne Genomics, Rockville, MD, USA),
Metacore (Thompson Reuters, New York City, NY, USA), and Inge-
nuity (Ingenuity Systems, Redwood City, CA, USA). These tools
enable the identification of the relationship among proteins, small
molecules, cell processes, and diseases. Pathway analysis provides
information on what is known to interact with the proteins that
are identified in the sample as well as association of these proteins
to cellular processes.
BIOMARKER APPLICATIONS
Clinically validated biomarkers are needed for the accurate diag-
nosis of mild TBI. This type of TBI is particularly hard to accurately
measure and the situation is, made more challenging by patients
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who sometimes hide their symptoms. There is no gold standard
yet for diagnosing mild TBI (Shenton et al., 2012), not even by
conventional assessment through neuroimaging techniques (Niogi
and Mukherjee, 2010). The lack of a consensus definition of mild
TBI further complicates the matter (Ruff and Jurica, 1999; Arcin-
iegas and Silver, 2001) and the challenge lies in accurate diagnosis
in managing post-injury. The Veteran’s Administration Clinical
Practice Guideline released a working document on criteria to
diagnose mild TBI. These diagnostic criteria include an initial
Glascow Coma Scale (GCS) of 13–15; less than a 30-min loss
of consciousness; post traumatic amnesia up to 24 h after the
injury and alteration of consciousness (Management of Concus-
sion/mTBI Working Group, 2009). Other factors may compound
this guideline. In addition to patients trying to hide the true injury,
proper diagnosis is compounded by alcohol ingestion,polytrauma,
sedatives, pain killers, and drugs of abuse.
A biomarker that is measurable in the blood would be use-
ful in these kinds of situations, where a polytrauma exists. It was
suggested that instead of using one biomarker, a panel of bio-
markers could be helpful. Mondello et al. (2012a) have explored
the ratio of GFAP and UCHL1 concentrations to assess patients
with severe TBI.
Another type of injury that needs to be addressed by biomarkers
from the blood is in diffuse axonal injury (Inglese et al., 2005). The
microstructural axonal damage in this kind of injury is believed
to be a challenge to detect by neuroimaging techniques such as
computed tomography and conventional MRI.
Drug discovery is one of the fields that will greatly bene-
fit from a signature marker for TBI. New therapeutic devel-
opment traditionally has an extremely high triage rate because
more than 90% of drugs that advance to Phase I clinical trials
fail. Some argue such extreme loss can be overcome by guid-
ing all new therapeutic development and clinical trials with a
disease-relevant diagnostic test. Discovery of translational bio-
marker (from animal studies to clinical trials) might help to
finally deliver the long sought after clinical trial success. “Ther-
anostics represents the convergence between Therapeutics and
diagnostics (Bissonnette and Bergeron, 2006; Hooper, 2006).” It
has been viewed as the parallel use of new therapy and diag-
nostic tests for a human disease or disorder so as to facilitate
drug development and clinical trials and to achieve optimal
clinical outcomes in a population of patients. Importantly, in
recognizing the emerging role of the theranostic approach, the
FDA has recently drafted a Drug-Diagnostic Co-Development
Concept Paper (Hinman et al., 2006) with the goal of setting
guidelines for prospective co-development of a drug or biologi-
cal therapy (drugs) and a device test in a scientifically robust and
efficient way.
One example of a theranostic approach to drug development is
a novel biomarker-guided approach in our laboratory that com-
bines calpain-generated acute brain injury-tracking biomarkers
with potent and selective calpain inhibitor drug candidates to fast-
track and improve the chances of successful drug development for
CNS injury. During brain injury, neural proteins or their break-
down products generated by calpains (µ-calpain and m-calpain)
are released into the extracellular environment and eventually
reach the CSF in relatively high concentration (Wang et al., 2005).
In due time the proteins reach the blood stream either via the com-
promised blood brain barrier (BBB or via filtration of the CSF).
Clearance and half-life of the biomarkers contribute to the final
concentration that can be measured in the blood. The CSF vol-
ume of an adult human (CSF 125–150 mL) is about 30- to 40-fold
less than the blood volume (4.5–5 L) which explains why the brain
biomarker concentration is significantly higher in the CSF sam-
ples versus blood samples and makes the former valuable for drug
development. Enabled by recent technological advances in pro-
teomics, novel brain injury biomarkers that have elevated levels in
biofluid such as CSF or blood after TBI have been discovered.
POSSIBLE BIOMARKERS FOR TRAUMATIC BRAIN INJURY
We now know that despite the efforts in brain injury research to
discover and develop disease tracking markers, currently there are
no clinically validated biomarkers to diagnose TBI. Even though
the search continues, several candidate biomarkers of TBI bio-
markers are in the clinical validation pipeline. Extensive studies
are being pursued to move these protein biomarkers to clini-
cal validation. The aforementioned techniques in proteomic have
been employed in the discovery for candidate biomarkers of TBI.
Kobeissy et al. identified 59 differentially proteins 48 h post TBI
using a CCI rat model. Proteins that were decreased in abun-
dance included CRMP-2, glyceraldehyde-3-phosphate dehydroge-
nase,microtubule-associated proteins MAP2A/2B,and hexokinase
(Kobeissy et al., 2006). Upregulated proteins included C-reactive
proteins, transferrin, and breakdown products of CRMP-2, synap-
totagmin, and alphaII-spectrin. Western blotting analysis con-
firmed the differential changes in the mentioned proteins. This
study provided insight into the mechanism of TBI and generated
candidate biomarkers that can aid in the evaluation of the sever-
ity and progression of injury as well as in the development of
possible therapies. The need for strengthening the role of systems
biology and its application to the field of neuroproteomics due
to its integral role in establishing a comprehensive understanding
of specific brain disorder and brain function in general was high-
lighted in a review by Kobeissy et al. (2008). The use of a systems
biology-based approach to drug discovery and development for
TBI based on the advances in genomics, proteomics, bioinformatic
tools, and systems biology software has been shown (Zhang et al.,
2010). Recently, Boutté et al. (2012) conducted a proteomic analy-
sis and brain-specific systems biology in a rodent model of PBBI.
In their study, a combination of two-dimensional gel electrophore-
sis and MS was used to screen for biomarkers in a rat model of
PBBI. Brain-specific systems biology analysis of brain tissue iden-
tified 321 upregulated and 65 downregulated proteins 24 h post
PBBI compared to sham controls. In their gene ontology analysis,
the majority of upregulated proteins were cytoskeletal (10.5%),
nucleic acid binding (9.3%), or kinases (8.9%). Most proteins
were involved in protein metabolism (22.7%), signal transduction
(20.4%), and development (9.6%). Pathway analysis indicated that
these proteins were involved in neurite outgrowth and cell differ-
entiation. Further confirmation of these proteins was conducted
using semi-quantitative Western blotting. Among these proteins
that indicated consistent increase in the brain tissue and CSF at
several time points post PPBI were UCHL1, tyrosine hydroxylase,
and syntaxin-6. Antibody-based platforms, antibody microarrays
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(AbMA), and reverse capture protein microarrays (RCPM) com-
plementing the classical methods based on 2D gel electrophoresis
and mass spectrometry (2DGE/MS) has been proposed for discov-
ery of potential biomarkers for blast neurotrauma (Agoston et al.,
2009). Kwon et al. (2011) combined behavioral, proteomics, and
histological studies to investigate stress and blast-induced TBI. In
this study, exposure to repeated stress alone showed a transient
increase in anxiety but no significant memory impairment or cel-
lular and molecular changes. In contrast, repeated stress and blast
resulted in lasting behavioral, molecular, and cellular abnormali-
ties characterized by memory impairment, neuronal and glial cell
loss, inflammation, and gliosis.
Listed below are examples of the most studied candidate protein
biomarkers for TBI. These represent potential biomarkers of TBI
that have shown high sensitivity and specificity in independent
studies. UCHL1, SBDPs, and neuron-specific enolase (NSE) are
presented as examples of neuronal and axonal protein biomark-
ers. For glial-specific markers, GFAP and S100beta are discussed
below.
UBIQUITIN CARBOXY-TERMINAL HYDROLASE L1 PROTEIN
Ubiquitin carboxy-terminal hydrolase L1 protein is a cysteine pro-
tease that is predominantly expressed in neurons, although it is also
expressed in small amounts in neuroendocrine cells. This enzyme
is relatively small, around 25 kDa and comprises∼2% of the total
soluble protein in the brain. The other name for this protein is
neuronal-specific protein gene product 9.5. Known function of
UCHL1 is that it hydrolyzes the C-terminal bond of ubiquitin or
unfolded polypeptides (Setsuie and Wada, 2007).
Several publications have indicated that UCHL1 can be a bio-
marker for TBI. Recently, the biokinetic parameters of UCHL1
were measured from a cohort of severely injured TBI patients
(Brophy et al., 2011). A more recent study (Mondello et al., 2012b)
demonstrated that UCHL1 can be used as a biomarker for severely
injured TBI patients. Compared to control, the serum UCHL1 lev-
els of TBI patients were significantly elevated measured after the
acute phase and then over a week.
SPECTRIN BREAKDOWN PRODUCTS
AlphaII-spectrin is primarily found in neurons and is concen-
trated in axons and presynaptic terminals (Riederer et al., 1986).
Upon activation in TBI, calpain cleaves the protein to breakdown
products (SBDPs) of molecular weights 150 kDa (SBDP150) and
145 kDa (SBDP145) and casapse-3 cleaves it to a 120-kDa prod-
uct (SBDP120). Calpain and caspase-3 are major executioners of
necrotic and apoptotic cell death, respectively, during ischemia
or TBI ( Ringger et al., 2004; Pineda et al., 2007; Mondello
et al., 2010;). SBDPs concurrently indicate calpain and caspase-3
proteolysis of alphaII-spectrin, providing crucial information on
the underlying cell death mechanisms. In CSF, distinct temporal
release patterns of SBDP145 and SBDP120 were observed to reflect
different temporal characteristics of protease activation (Mondello
et al., 2010). Elevated levels of SBDPs in CSF from adults with
severe TBI were reported and their significant relationships with
severity of injury and outcome (Pineda et al., 2007). Increased
CSF SBDP levels were found to be significantly associated with
mortality in patients with severe TBI. The temporal profile of
SBDPs in non-survivors was also found to be different those of
survivors (Mondello et al., 2010). Taken together, these findings
suggest that SBDPs may provide crucial information not only on
severity of brain injury, but also on underlying pathophysiological
mechanisms associated with necrotic and apoptotic cell death.
NEURON-SPECIFIC ENOLASE
Neuron-specific enolase is a glycolytic pathway enzyme and highly
expressed in neuronal cytoplasm. NSE has been shown to have the
sensitivity and specificity to detect neuronal cell death (Selakovic
et al., 2005). In addition, studies have been conducted examining
CSF and serum NSE levels from adults with severe TBI, and their
relationship with severity of injury and clinical outcome. Increased
CSF and serum levels of NSE have been reported after TBI. NSE
concentrations were also associated with severity of injury, CT
scan findings, and outcome (Ross et al., 1996; Herrmann et al.,
2000; Selakovic et al., 2005).
GLIAL FIBRILLARY ACIDIC PROTEIN
Of the numerous candidate biomarkers for TBI, this protein holds
the most promise. One of the strengths of GFAP as an ideal bio-
marker for TBI is that this protein is not found outside the central
nervous system (Galea et al., 1995). First reported in 1971 (Eng
et al., 1971), GFAP is found only in astroglial cytoskeleton. GFAP
is an intermediate filament protein that forms networks that sup-
port the astroglial cells. Damage to the astroglial cells (astrogliosis)
shows subsequent upregulation of GFAP. During injury, astroglial
cells react by producing more GFAP. Evidence shows that serum
GFAP is elevated with several types of brain damage, including
TBI (Pelinka et al., 2004a,b; Nylén et al., 2006).
What makes GFAP specific to brain trauma is that even if the
body is subjected to multiple forms of trauma, GFAP doesn’t spike
up without brain injury (Pelinka et al., 2004b; Vos et al., 2004).
Thus, GFAP as a biomarker is a specific indicator of injury to the
glia. There’s also a high likelihood that GFAP can predict death or
unfavorable outcomes (Vos et al., 2010; Zurek and Fedora, 2012).
According to the proceedings of the military mild TBI diagnos-
tic workshop (2010), validation studies in humans are already
on-going (Marion et al., 2011).
S100ß
S100ß is mainly found in astroglia and Schwann cells (Donato,
1986; Donato et al., 1986a,b), and is one of the most well-known
biomarkers of brain damage. The concentration of S100ß is known
to increase in the CSF and serum after injury making this protein
a potential biomarker for TBI (Townend et al., 2006). This protein
is not influenced by hemolysis and has a biological half-life of 2 h.
S100ß belongs to a family of low molecular weight (9–13 kDa)
calcium-binding S100 proteins and is involved in signal transduc-
tion (Heizmann et al., 2002). Several studies have examined the
value of this marker, demonstrating correlation with injury and
outcome (Pelinka et al., 2003a; Berger et al., 2005; Kleindienst et al.,
2007; Egea-Guerrero et al., 2012). However, several limitations
have been found. First, S100ß is not specific to the brain, showing
up in non-nervous cells such as adipocytes, epidermal, chon-
drocytes, melanoma cells, and Langerhans cells (Zimmer et al.,
1995). The presence of this protein outside the central nervous sys-
tem is compounded by the problem that general trauma without
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brain injury can increase the said protein (Rothoerl and Woertgen,
2001). Second, S100ß spikes up after hemorrhagic shock, correlat-
ing the concentration to shock severity (Pelinka et al., 2003a,b,c).
Because of this, it seems that S100ß cannot be used as a single
biomarker for TBI. A recent study has looked at the ratio of S100ß
against GFAP (Pelinka et al., 2004a), instead of looking at S100ß
alone. In the study, the ratio of GFAP against S100ß was used to
determine brain damage and prognosis. In another study, S100ß
seemed to be a useful indicator of patients with intracranial lesion
(Egea-Guerrero et al., 2012).
Another limitation in using S100ß as a biomarker for TBI is the
relatively short serum half-life (Jackson et al., 2000). The obvious
countermeasure to this problem is to measure the proteins right
after injury; however, most mild TBI victims are not evaluated as
soon as the injury occurs.
CONCLUSION
Proteomics, with the advancement in MS along with the bioinfor-
matics software, has opened opportunities to interrogate protein
dynamics and provide insights into the biochemistry of TBI. Over
the past years, proteomics has led to the discovery of many can-
didate biomarkers and is becoming the method-of-choice for
preliminary candidate marker selection. However, identification
of candidate biomarkers using this approach is proving to be only
the initial step in the development of a useful biomarker. Systems
biology coupled to data mining strategies has been applied to
harness these large data sets into organized and interlinked data-
bases that can be queried to identify non-redundant brain injury
pathways. The pathways can be exploited to determine the utili-
ties of these proteins as diagnostic biomarkers and/or therapeutic
targets.
This review provides an overview of the integration of pro-
teomics, bioinformatics, and systems biology in TBI biomarker
discovery. At present, proteomic biomarker discovery experiments
have generated a long list of TBI biomarker candidates. Clearly, the
next step is translating a robust biomarker or panel of biomark-
ers to clinical use. Currently, sensitive and specific immunoassays
are being developed to validate a number of TBI biomarkers in
clinical samples. However, the high cost of assay development and
availability of antibodies result in a bottleneck in the clinical vali-
dation pipeline of the long list of discovered potential biomarkers.
Targeted proteomics is a growing trend among the proteomic com-
munity. Mass spectrometry-based measurements such as multiple
reaction monitoring (MRM) is a promising technique that could
revolutionize biomarker validation. The current technologies are
still evolving to address fundamental problems in identifying low
abundant protein biomarkers such as in the case of mild TBI.
The trend of lower costs, highly sensitive instruments (Orbitrap),
and better electronic hardware will most likely increase targeted
proteomics experiments in the future.
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